NEOG
Neogen Corporation
⚡ 1-Minute Take
- Upcoming: Launch of new diagnostic test kits for emerging foodborne pathogens.
- Ongoing: Expansion of genomics testing services for livestock and companion anim
- Ongoing: Strategic acquisitions to broaden product portfolio and market reach.
- Potential: Intense competition from established players in the diagnostics and a
- Potential: Changes in regulatory requirements affecting product approvals and ma
- Next earnings report and guidance
- Analyst consensus and price targets
Data sources: market data, fundamentals, news providers. Data may be delayed.
Company Overview
Key Statistics
MoonshotScore Breakdown: 46.5/100
📰 Latest News
Neogen Corporation ensures global food and animal safety through its comprehensive diagnostic and genetic solutions. With a focus on innovation and quality, Neogen empowers producers and processors to protect their products and animals, driving growth in a critical and expanding market.
About NEOG
Neogen Corporation develops, manufactures, and markets products for food and animal safety. The company operates through Food Safety and Animal Safety segments, offering diagnostic test kits, pharmaceuticals, and genomics testing services.
Neogen Corporation Company Overview
Neogen Corporation, founded in 1981 and headquartered in Lansing, Michigan, is a global leader in developing, manufacturing, and marketing a diverse range of products dedicated to food and animal safety. The company operates through two primary segments: Food Safety and Animal Safety. The Food Safety segment provides diagnostic test kits and related products designed to detect dangerous and unintended substances in food and animal feed. These include solutions for identifying foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, and drug residues. Neogen's Food Safety products cater to a wide array of customers, including food and feed producers, processors, laboratories, and manufacturers of pharmaceuticals and cosmetics. The Animal Safety segment offers a comprehensive portfolio of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services. These products serve the animal safety market, supporting researchers in detecting biologically active substances and maintaining sanitary conditions. Neogen's drug detection immunoassay test kits are utilized for detecting abused and therapeutic drugs in farm and racing animals, as well as for human forensic toxicology drug screening applications. Neogen's commitment to innovation and quality has solidified its position as a trusted partner in the food and animal safety industries worldwide.
Investment Thesis
Neogen Corporation presents a compelling investment opportunity driven by its critical role in ensuring food and animal safety globally. The increasing focus on food safety regulations and animal health standards is expected to drive demand for Neogen's diagnostic and genetic solutions. While the company's current P/E ratio is -3.90 and profit margin is -68.5%, this is influenced by recent merger-related expenses, and the underlying business demonstrates strong growth potential. Key value drivers include expanding its genomics testing services and leveraging its established distribution network. The company's robust product portfolio and strategic acquisitions position it for sustained growth in the long term. Investors should consider Neogen for its potential to capitalize on the growing need for advanced safety solutions in the food and animal industries.
Key Financial Highlights
- Market Cap of $2.35B reflects Neogen's significant presence in the food and animal safety market.
- Gross Margin of 38.0% indicates a solid ability to manage production costs and maintain profitability in its core product lines.
- Beta of 1.98 suggests that the stock is more volatile than the market, potentially offering higher returns but also greater risk.
- Neogen operates in two segments, Food Safety and Animal Safety, providing diversification and resilience to market fluctuations.
- Neogen's focus on diagnostic and genetic solutions aligns with increasing global concerns about foodborne illnesses and animal health.
Industry Context
Neogen operates within the growing medical diagnostics and research industry, driven by increasing concerns over food safety and animal health. The market for food safety diagnostics is expanding due to stricter regulations and consumer demand for safer products. Similarly, the animal health market is growing, fueled by the increasing importance of livestock management and disease prevention. Neogen competes with companies like AZTA (Azenta, Inc.), BLFS (BioLife Solutions, Inc.), CNMD (CONMED Corporation), KMTS (KMT Medical Technology Co., Ltd.), and NTLA (Intellia Therapeutics, Inc.), each with its own specialization within the broader healthcare and life sciences landscape. Neogen's focus on both food and animal safety provides a diversified approach to capitalize on these trends.
Quarterly Financial Summary
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $225M | -$16M | $-0.07 |
| Q3 2025 | $209M | $36M | $0.17 |
| Q2 2025 | $225M | -$612M | $-2.82 |
| Q1 2025 | $221M | -$11M | $-0.05 |
Source: Company filings. Data may be delayed.
Growth Opportunities
- Expansion of Genomics Services: Neogen has a significant opportunity to expand its genomics services within the animal safety market. The increasing demand for genetic testing in livestock and companion animals, driven by precision breeding and disease management, presents a substantial growth avenue. By leveraging its existing infrastructure and expertise, Neogen can capture a larger share of the genomics market, estimated to reach $6.5 billion by 2028, enhancing revenue and profitability.
- Strategic Acquisitions: Neogen can pursue strategic acquisitions to broaden its product portfolio and expand its market reach. Acquiring companies with complementary technologies or geographic presence can accelerate growth and enhance Neogen's competitive position. This strategy allows Neogen to quickly enter new markets or product segments, capitalizing on synergies and economies of scale. The market for acquisitions in the diagnostics and animal health space remains active, providing ample opportunities for Neogen to enhance its value proposition.
- Increased Focus on Food Safety Regulations: The growing stringency of food safety regulations worldwide presents a significant growth opportunity for Neogen. As governments and consumers demand higher standards for food safety, the demand for Neogen's diagnostic test kits and related products will increase. By staying ahead of regulatory changes and developing innovative solutions to meet these evolving needs, Neogen can solidify its position as a trusted partner for food producers and processors.
- Penetration of Emerging Markets: Neogen has the opportunity to expand its presence in emerging markets, where the demand for food and animal safety solutions is rapidly growing. These markets often have less developed regulatory frameworks and infrastructure, creating a need for Neogen's expertise and products. By establishing strategic partnerships and tailoring its offerings to local needs, Neogen can tap into the significant growth potential of these markets, driving revenue and expanding its global footprint.
- Development of Innovative Diagnostic Technologies: Investing in the development of innovative diagnostic technologies can provide Neogen with a competitive edge and drive future growth. By focusing on developing faster, more accurate, and more cost-effective diagnostic solutions, Neogen can attract new customers and retain existing ones. This includes exploring technologies such as molecular diagnostics, biosensors, and data analytics to enhance its product offerings and address emerging threats in food and animal safety.
Competitive Advantages
- Strong brand reputation and established relationships with key customers.
- Proprietary diagnostic technologies and intellectual property.
- Extensive distribution network and global reach.
- High switching costs for customers due to regulatory requirements and validation processes.
Strengths
- Comprehensive product portfolio in food and animal safety.
- Strong brand reputation and customer loyalty.
- Global distribution network.
- Experienced management team.
Weaknesses
- Negative profit margin (-68.5%) due to merger-related expenses.
- High beta (1.98) indicating higher volatility.
- Dependence on regulatory approvals for new products.
Opportunities
- Expansion of genomics services.
- Strategic acquisitions to broaden product portfolio.
- Increased focus on food safety regulations.
- Penetration of emerging markets.
Threats
- Intense competition from established players.
- Changes in regulatory requirements.
- Economic downturn affecting customer spending.
- Potential product liability claims.
What NEOG Does
- Develops and manufactures diagnostic test kits for food safety.
- Provides solutions for detecting pathogens, toxins, and allergens in food.
- Offers veterinary instruments and pharmaceuticals for animal health.
- Provides genomics testing services for livestock and companion animals.
- Manufactures cleaners, disinfectants, and insecticides for animal safety.
- Offers drug detection immunoassay test kits for farm and racing animals.
- Develops products to maintain sanitary conditions and limit potential hazards.
Business Model
- Sales of diagnostic test kits and related products to food producers and processors.
- Sales of veterinary pharmaceuticals, vaccines, and instruments to animal health professionals.
- Provision of genomics testing services for animal breeding and disease management.
- Distribution of products through a network of distributors and direct sales.
Key Customers
- Food and feed producers and processors.
- Meat and poultry processors.
- Veterinarians and animal health professionals.
- Laboratories and research institutions.
- Pharmaceutical and cosmetic manufacturers.
Competitors
- Azenta, Inc. (AZTA): Provides life sciences solutions, including genomics services.
- BioLife Solutions, Inc. (BLFS): Specializes in biopreservation tools and services.
- CONMED Corporation (CNMD): Offers surgical and patient monitoring products.
- KMT Medical Technology Co., Ltd. (KMTS): Focuses on medical devices and equipment.
- Intellia Therapeutics, Inc. (NTLA): Develops CRISPR-based gene editing therapies.
Catalysts
- Upcoming: Launch of new diagnostic test kits for emerging foodborne pathogens.
- Ongoing: Expansion of genomics testing services for livestock and companion animals.
- Ongoing: Strategic acquisitions to broaden product portfolio and market reach.
- Ongoing: Increasing global focus on food safety and animal health regulations.
Risks
- Potential: Intense competition from established players in the diagnostics and animal health markets.
- Potential: Changes in regulatory requirements affecting product approvals and market access.
- Ongoing: Economic downturn affecting customer spending on food and animal safety products.
- Potential: Product liability claims related to the safety and efficacy of Neogen's products.
- Ongoing: Integration challenges related to recent mergers and acquisitions.
FAQ
What does Neogen Corporation (NEOG) do?
Neogen Corporation develops, manufactures, and markets products for food and animal safety. The company operates through Food Safety and Animal Safety segments, offering diagnostic test kits, pharmaceuticals, and genomics testing services.
Why does NEOG move today?
Stock prices move due to earnings, news, market sentiment, and sector trends. Check the News tab for recent developments affecting NEOG.
What are the biggest risks for NEOG?
Potential: Intense competition from established players in the diagnostics and animal health markets.. Potential: Changes in regulatory requirements affecting product approvals and market access.
How should beginners use this page?
Start with the 1-Minute Take for a quick summary. Review Key Statistics for fundamentals. Check the News tab for recent developments. Use our Portfolio Tracker to practice without real money. Never invest more than you can afford to lose.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Related Stocks in Medical - Diagnostics & Research
Browse More
Next Steps
Data provided for informational purposes only. View more at Stock Expert AI
Last updated: 2026-02-21T01:36:38.498Z